Gene expression tests for women with early stage breast cancer : a review of clinical utility and cost-effectiveness

Gene expression tests for women with early stage breast cancer : a review of clinical utility and cost-effectiveness /

While each gene expression test has been independently clinically validated using prospective or retrospective evidence, currently, there is no gold-standard for breast cancer gene expression tests. This highlights the need for comparative assessments of clinical utility and cost-effectiveness.

Saved in:
Bibliographic Details
Online Access: http://www.ncbi.nlm.nih.gov/books/NBK513363/
Full text
Main Authors: Narain, Tasha (Author), Adcock, Lorna (Author)
Format: Electronic eBook
Language:English
Published: Ottawa (ON) : Canadian Agency for Drugs and Technologies in Health, 2017
Edition:Version 1.0.
Series:Rapid response report (Canadian Agency for Drugs and Technologies in Health)
Subjects:
Breast Neoplasms.
Gene Expression Regulation, Neoplastic.
Neoplasm Recurrence, Local.
Chemotherapy, Adjuvant.
Cost-Benefit Analysis.
Review.

MARC

LEADER 00000cam a2200000 i 4500
001 p2436845
005 20240212122441.0
006 m o d
007 cr cn ||||||||
008 190102s2017 onca on 000 0 eng
035 |a (DNLM)BKSHLF:NBK513363 
035 |9 101740490 
035 |a 1740490 
040 |a DNLM  |b eng  |e rda  |c DNLM  |d UtOrBLW 
041 0 9 |a eng 
044 |9 Canada 
060 0 0 |a WP 870 
100 1 |a Narain, Tasha,  |e author.  |0 n 2018186055 
245 1 0 |a Gene expression tests for women with early stage breast cancer :  |b a review of clinical utility and cost-effectiveness /  |c Tasha Narain, Lorna Adcock. 
250 |a Version 1.0. 
264 1 |a Ottawa (ON) :  |b Canadian Agency for Drugs and Technologies in Health,  |c October 16, 2017. 
300 |a 1 online resource (1 PDF file (14 pages)) :  |b illustrations. 
336 |a text  |b txt  |2 rdacontent 
337 |a computer  |b c  |2 rdamedia 
338 |a online resource  |b cr  |2 rdacarrier 
490 1 |a Rapid response report: summary with critical appraisal,  |x 1922-8139 
520 3 |a While each gene expression test has been independently clinically validated using prospective or retrospective evidence, currently, there is no gold-standard for breast cancer gene expression tests. This highlights the need for comparative assessments of clinical utility and cost-effectiveness. 
588 |a Description based on online resource; title from PDF title page (viewed February 11, 2019). 
650 1 2 |a Breast Neoplasms.  |0 D001943 
650 2 2 |a Gene Expression Regulation, Neoplastic.  |0 D015972 
650 2 2 |a Neoplasm Recurrence, Local.  |0 D009364 
650 2 2 |a Chemotherapy, Adjuvant.  |0 D017024 
650 2 2 |a Cost-Benefit Analysis.  |0 D003362 
655 2 |a Review.  |0 D016454 
700 1 |a Adcock, Lorna,  |e author.  |0 n 2019181079 
710 2 |a Canadian Agency for Drugs and Technologies in Health,  |e issuing body.  |0 n 2007182676 
830 0 |a Rapid response report (Canadian Agency for Drugs and Technologies in Health)  |0 no2011185412 
856 4 0 |u http://www.ncbi.nlm.nih.gov/books/NBK513363/  |t 0 
951 |a 2436845 
992 |p P2  |e EF  |a 20190102 
993 |a EXL  |b 20190125 
995 |a AUTH  |b 20190211  |c REV  |d 20190213 
998 |a BKSHLF  |b 20190102 
998 |a FER  |b 20190102 
999 |a AUTH 
999 f f |i 9b46d446-6185-505c-ba02-e023d89e7f72  |s fe5c7462-d113-550a-a034-5845c1d33940  |t 0 
952 f f |a Massachusetts College of Pharmacy and Health Sciences  |b Online  |c Online  |d E-Collections  |t 0  |e NCBI  |h Other scheme 
856 4 0 |t 0  |u https://www.ncbi.nlm.nih.gov/books/NBK513363/  |y Full text 

Similar Items